all patients | p53 wild type | |||||||
---|---|---|---|---|---|---|---|---|
p53 codon 72 Arg/Arg | p53 codon 72 Pro/Pro | p53 codon 72 Arg/Pro | p | p53 codon 72 Arg/Arg | p53 codon 72 Pro/Pro | p53 codon 72 Arg/Pro | p | |
γ-irradiation (% surviving cells) | 36.3 ± 4.7 (n = 49) | 50.0 ± 10.1 (n = 7) | 24.2 ± 4.8 (n = 26) | 0.099 | 30.6 ± 4.8 (n = 39) | 54.7 ± 13.4 (n = 5) | 22.9 ± 4.9 (n = 25) | 0.14 |
log10 LC90 chlorambucil | 0.73 ± 0.07 (n = 78) | 0.76 ± 0.19 (n = 9) | 0.62 ± 0.08 (n = 49) | 0.63 | 0.6 ± 0.08 (n = 61) | 0.76 ± 0.22 (n = 7) | 0.57 ± 0.08 (n = 46) | 0.70 |
log10 LC90 mafosfamide | 0.32 ± 0.05 (n = 75) | 0.37 ± 0.12 (n = 9) | 0.21 ± 0.05 (n = 47) | 0.39 | 0.3 ± 0.06 (n = 59) | 0.38 ± 0.16 (n = 7) | 0.21 ± 0.05 (n = 44) | 0.42 |
log10 LC90 fludarabine | 0.18 ± 0.08 (n = 78) | 0.13 ± 0.18 (n = 9) | -0.32 ± 0.1 (n = 49) | 0.32 | 0.11 ± 0.1 (n = 61) | 0.22 ± 0.23 (n = 7) | -0.06 ± 0.01 (n = 46) | 0.28 |
log10 LC90 cladribine | -0.76 ± 0.1 (n = 78) | -0.85 ± 0.18 (n = 9) | -1.0 ± 0.11 (n = 49) | 0.10 | -0.89 ± 0.1 (n = 61) | -0.79 ± 0.22 (n = 7) | -1.04 ± 0.11 (n = 46) | 0.22 |
log10 LC90 vincristine | 0.13 ± 0.1 (n = 55) | 0.01 ± 0.27 (n = 8) | -0.22 ± 0.11 (n = 39) | 0.71 | -0.14 ± 0.11 (n = 40) | 0.05 ± 0.33 (n = 6) | -0.25 ± 0.11 (n = 36) | 0.59 |
log10 LC90 doxorubicin | -0.55 ± 0.04 (n = 78) | -0.52 ± 0.06 (n = 9) | -0.61 ± 0.05 (n = 49) | 0.64 | -0.55 ± 0.05 (n = 61) | -0.49 ± 0.07 (n = 7) | -0.63 ± 0.05 (n = 46) | 0.35 |
log10 LC90 methylprednisolone | 0.99 ± 0.14 (n = 78) | 1.36 ± 0.45 (n = 9) | 0.95 ± 0.18 (n = 48) | 0.70 | 0.99 ± 0.16 (n = 61) | 1.52 ± 0.47 (n = 7) | 0.95 ± 0.18 (n = 45) | 0.57 |